Loading the companies…
Loading the companies…
Loading the companies…
Companies › Competitive landscape
49 companies on innovation pace, recall and report signals, commercial momentum and financial capacity, each against the others in tumor & fibroid embolization. The procedure’s market
In 2025, 27 companies spent $17M in consulting, speaking, meals and travel tied to tumor & fibroid embolization products with the surgeons MedaRep tracks; Exact Sciences spent the most, 24%. Royalties are left out.
In 2025, surgeons Boston Scientific engaged on tumor & fibroid embolization products did 12% of the family’s Medicare cases, the most of any company; since 2019, Boston Scientific’s share has moved the most, +11 pts. 74% of cases sit with surgeons no company engaged past $500 for these products: where a line you carry meets the least engagement. See who they are in your territory.
| Firm | Cases | Share | Surgeons | Full reach | Reported |
|---|---|---|---|---|---|
| Boston Scientific | 1,266 | 12% | 67 | 1,599 | $1.4M |
| Sirtex Medical | 673 | 6% | 32 | 1,194 | $1.0M |
| Other firms | 855 | 8% | 17+ | 546+ | $1.0M |
| No tie over $500 | 7,750 | 74% | 221 |
10,544 Medicare cases by 320 surgeons; 26% sit with surgeons at least one firm engaged past $500 in 2025. Your plan names the top 3 firms; paid plans name eight.
Click a year to show it in the donut and table. Years after 2024 reuse that year’s cases, the newest Medicare file.
| Firm · cases | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Boston Scientific | 80 | 187 | 618 | 1,199 | 1,491 | 1,736 | 1,266 |
| Sirtex Medical | 660 | 784 | 738 | 647 | 579 | 544 | 673 |
| Other firms | 1,439 | 261 | 680 | 618 | 553 | 812 | 855 |
| No tie over $500 | 4,285 | 4,562 | 4,372 | 4,044 | 5,423 | 7,452 | 7,750 |
A company is counted for a surgeon when its Open Payments to them in a program year total more than $500 (devices and supplies; drug and biological payments left out). The surgeon’s Medicare fee-for-service cases for tumor & fibroid embolization then count toward the company, a surgeon several companies engage split between them by dollars, so the slices add up to the family’s cases in the states loaded. Switch the ribbon to dollars to read engagement instead of volume. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Cases lag payments, so each payment year is read against the latest Medicare year at or before it.
Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. FDA counts are 510(k), De Novo and PMA decisions under the category’s product codes.